The EDGE™ Radiosurgery System

The EDGE™ Radiosurgery System for Cancer Treatment

The EDGE™ Radiosurgery system is a fully integrated, dedicated system for performing advanced radiosurgery using new real-time tumor tracking technology and motion management capabilities.

CCS  is pleased to announce the first and only Edge radiosurgery system in WNY, available at our new Orchard Park location.

Edge imageMany clinics worldwide have already adopted Edge technology to help advance the way cancer is treated.

Using technology designed for radiosurgical ablation, the Edge™ radiosurgery system represents an evolution in the way advanced radiosurgery is delivered.

The Edge™ radiosurgery system provides a turn-key solution for delivering full-body radiosurgery treatments with accuracy.

Edge offers advanced tools designed to deliver highly conformal dose distributions to tumors of the lung, brain, spine, and other areas of the body where radiation is indicated.

One of the key aspects of radiosurgery is precision and accuracy.

Edge radiosurgery tracks the patient’s tumor in real time for intracranial and extracranial treatments, precisely calculates patient movement in all six degrees of freedom, and monitors respiratory motion.

It includes capabilities such as:

  • High dose radiation delivery of up to 2400 monitor units per minute
  • A new bed that adjusts on six axes
  • Continuous correction of beam targeting every ten milliseconds.
  • The 6 degree freedom couch allows for accurate patient positioning.

A growing body of clinical evidence is demonstrating the benefits of delivering high doses in a small number of fractions.

Starting from classical neurosurgical targets, Stereotactic Radiosurgery (SRS) is progressing to treat targets previously not considered candidates for high-dose, hyprofractionated delivery.

The ability to accurately deliver targeted treatments and manage tumor motion is driving growth in radiosurgery.

A 108% increase in SRS utilization for brain cancer treatments is predicted over the next 10 years. SRS treatment volume is expected to grow 93% and Stereotactic Body Radiation Therapy (SBRT) volume is expected to grow 144% within the next 10 years.

  • These numbers are suggestive of the high level of confidence that clinicians have in targeting tumors with precision.

Having the power to not only treat quickly, but to deliver high, accurate dose rates are hallmarks of the Edge system.